PHILADELPHIA, PA (May 13, 2009)-A new advocacy group, The Patient Recruitment Organization (PRO) Steering Committee, has been formed to represent the international patient recruitment and retention industry. The committee's goal is to identify and address ongoing issues to help strengthen this niche industry. The group convened recently in Philadelphia to discuss core issues impacting patient recruitment organizations.
The PRO Steering Committee comprises a select delegation of patient recruitment leaders. The first summit was held April 16 at the Westin Philadelphia and drew executives from top patient recruitment organizations, including D. Anderson Company (DAC), Fleishman-Hillard Clinical Trials Division, Healthcare Communications Group, On The Scene Productions, Inc., (Pi) Patient interaction, RxTrials, and The Patient Recruiting Agency£ (TPRA). The event was co-hosted by Dallas, Texas-based DAC and Austin, Texas-based TPRA.
"Our discussions centered on several market trends which underscore the need for greater collaboration and cooperation among PROs," said Diana Anderson, Ph.D., president and CEO of DAC.
TPRA President Lance Nickens added, "It is exciting that competitors can come together in an effort to uplift the industry. By uniting in this way and jointly participating in education and standardization, we can influence everything from public perception to public policy."
The committee identified five areas of interest for advancing the patient recruitment and retention industry, namely, whether to form a professional trade organization; risk sharing; identifying industry trends; expanding globally; and improving how patient recruitment organizations work with stakeholders, including pharmaceutical and biotechnology companies, contract research organizations and clinical trial sites.
The PRO Steering Committee's next steps include broadening participation in the committee to other patient recruitment organizations and developing a position paper summarizing their strategies. The group will hold monthly teleconferences and re-convene in person within 12 months.
About The Patient Recruitment Organization (PRO) Steering Committee:
The PRO Steering Committee is an ad hoc group of professionals who lead patient recruitment organizations. The goal of the committee is to work together to address issues and trends that impact the provision of their patient recruitment and retention services globally.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.